. 2021 Jun 2;30(1):19–27. doi: 10.4062/biomolther.2021.047
Copyright © 2022, The Korean Society of Applied Pharmacology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fig. 5.
Third-generation EGFR inhibitors.